1 0

    FDA Updated Complaints Related to Hims Products and Compounding Pharmacies

    FDA Updated Complaints Related to Hims Products and Compounding Pharmacies

    $69.00 USD
    $69.00 USD
    Sale Sold out
    Original Request: Please provide us with any and all updates to previous complaints received related to the safety of Hims’s products, including, but not limited to, complaints related to Hims’s compounding, complaints addressed to Hims’s compounding pharmacies (Apostrophe and XeCare), and complaints that Hims violates the FDCA by selling unapproved new drug products. This would be an update to the response given in reply to FOIA Control numbers 2024-2042 and 2024-2043.
    Tags: Pharma, Adverse Event, 2024
    • Status: Pending Fast-Track Request
    • Delivery: Approximately 1 to 2 weeks when the FOIA office is operating at regular capacity

    NOTE: This document is not currently in our library. Upon purchase, we will request the document from the FDA FOIA office. Learn more about Fast-Track Requests here.

    View full details